费瑞莫司醇增强MRI在恶性脑病变患者中优于平扫成像
前瞻性盲法重读研究纳入153例已知或疑似轴内原发性恶性或转移性脑肿瘤患者,3名独立神经放射科读者在独立阅片会话中对随机排序的费瑞莫司醇增强、钆增强或平扫图像进行评分。费瑞莫司醇增强MRI在对比增强程度、边界勾画和内部形态三个主要终点上均显著高于平扫图像(P < .001),安全性良好。
要点
- 费瑞莫司醇增强MRI在病灶对比增强程度、边界勾画和内部形态上均显著优于平扫(P < .001)。
- 费瑞莫司醇在肾功能不全患者中不禁忌,可作为钆基对比剂的潜在临床替代。
- 费瑞莫司醇给药耐受良好,不良事件与其作为铁替代治疗的特征一致。
核心结论
- 费瑞莫司醇增强MRI较平扫成像改善病灶可视化,作为脑肿瘤MRI对比剂在合适患者群体中可能为钆基对比剂提供有价值的临床替代。
研究设计与样本
- 前瞻性盲法重读研究,纳入153例已知或疑似轴内原发性恶性或转移性脑肿瘤患者(中位年龄54岁,57%男性,92%白人),3名独立神经放射科读者在独立合同研究组织安排的独立阅片会话中盲法评估随机排序的费瑞莫司醇增强、钆增强或平扫图像。
诊断标准与关键数值
- 采用4分可视化量表(1=无/差;4=优)评估对比增强程度、边界勾画和内部形态三个主要终点。费瑞莫司醇增强图像跨读者平均均值得分:对比增强2.8、边界勾画3.0、内部形态2.6;平扫图像相应得分分别为1.0、2.1、1.7(P < .001)。
临床应用与阅片要点
- 费瑞莫司醇增强MRI在对比增强程度、边界勾画和内部形态上均显著优于平扫,作者认为在合适患者群体中可能为钆基对比剂提供有价值的临床替代。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND AND PURPOSE: Patients with suspected brain tumors typically undergo an MRI with an IV contrast agent to detect regions of disrupted BBB caused by the tumor. Gadolinium-based contrast agents are standard for enhancing lesion visualization but may be contraindicated in patients with renal insufficiency. Ferumoxytol is an iron oxide nanoparticle approved for the treatment of iron deficiency anemia, and unlike gadolinium-based contrast agents, is not contraindicated in patients with renal impairment. Our study aimed to evaluate whether ferumoxytol-enhanced MRI is superior to precontrast imaging for structural delineation of intra-axial malignant brain lesions.
MATERIALS AND METHODS: This was a prospective, blinded reread study of MR images from patients with known or suspected intra-axial primary malignant or metastatic brain tumors, enrolled in an Institutional Review Board-approved research study, to support an FDA New Drug Application. Following FDA guidance, 3 independent neuroradiologist readers, blinded to contrast agent information, evaluated brain lesions of randomly ordered ferumoxytol-enhanced, gadolinium-enhanced, or precontrast images in separate reading sessions organized by an independent contract research organization. The 3 primary end points were the degree of contrast enhancement (CE), border delineation (BD), and the internal morphology (IM) of lesions, assessed using a 4-point visualization scale (1 = none/poor; 4 = excellent).
RESULTS: In total, 153 patients were enrolled in the study (median age, 54 years; 57% men; 92% white). All 3 readers scored ferumoxytol-enhanced MR images significantly higher than the precontrast images for visualizing lesions (P < .001 for each primary end point). Average mean scores across readers for ferumoxytol-enhanced images were 2.8 for CE, 3.0 for BD, and 2.6 for IM, compared with 1.0, 2.1, and 1.7, respectively, for the precontrast images (P < .001 for all). Safety data indicated that ferumoxytol administration was well-tolerated with adverse events consistent with its profile as an iron-replacement therapy.
CONCLUSIONS: This study provides robust evidence that ferumoxytol-enhanced MRI improves lesion visualization compared with precontrast imaging. Ferumoxytol, as an MRI contrast agent in brain tumor imaging, may provide a valuable clinical alternative to gadolinium-based contrast agents in appropriate patient groups.
引用
- Strauss WE, Fu R, Szidonya LK, et al. Superiority of Ferumoxytol MRI over Precontrast Imaging in Patients with Malignant Brain Lesions. AJNR Am J Neuroradiol. 2026. PMID: 41565357. doi:10.3174/ajnr.A9172
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。